Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.33 Million USD | -1011.02% |
| 2022 | 432.67 Thousand USD | 104.13% |
| 2021 | -10.48 Million USD | -22.59% |
| 2020 | -8.55 Million USD | 4.27% |
| 2019 | -8.93 Million USD | -45.41% |
| 2018 | -6.14 Million USD | -16.33% |
| 2017 | -5.28 Million USD | -33.85% |
| 2016 | -3.94 Million USD | 38.24% |
| 2015 | -6.38 Million USD | -800.9% |
| 2014 | -709.15 Thousand USD | 15.24% |
| 2013 | -836.61 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.36 Million USD | -35.33% |
| 2024 Q1 | -1.02 Million USD | -47.46% |
| 2023 Q3 | -772.91 Thousand USD | 23.67% |
| 2023 FY | -3.94 Million USD | -1011.02% |
| 2023 Q1 | -1.46 Million USD | -122.75% |
| 2023 Q2 | -1.01 Million USD | 30.83% |
| 2023 Q4 | -692.2 Thousand USD | 10.44% |
| 2022 Q2 | -1.71 Million USD | 34.06% |
| 2022 Q1 | -2.59 Million USD | 82.12% |
| 2022 FY | 432.67 Thousand USD | 104.13% |
| 2022 Q4 | 6.43 Million USD | 470.05% |
| 2022 Q3 | -1.73 Million USD | -1.63% |
| 2021 FY | -10.48 Million USD | -22.59% |
| 2021 Q2 | -4.54 Million USD | -70.09% |
| 2021 Q1 | -2.66 Million USD | 20.45% |
| 2021 Q3 | -3.01 Million USD | 33.59% |
| 2021 Q4 | -14.52 Million USD | -381.55% |
| 2020 Q1 | -2.33 Million USD | 42.84% |
| 2020 Q3 | -2.15 Million USD | -203.81% |
| 2020 Q4 | -3.35 Million USD | -55.95% |
| 2020 FY | -8.55 Million USD | 4.27% |
| 2020 Q2 | -708.22 Thousand USD | 69.68% |
| 2019 Q2 | -2.81 Million USD | -138.02% |
| 2019 Q3 | -2.41 Million USD | 14.21% |
| 2019 Q4 | -4.08 Million USD | -69.41% |
| 2019 FY | -8.93 Million USD | -45.41% |
| 2019 Q1 | -1.18 Million USD | 12.87% |
| 2018 Q4 | -1.35 Million USD | -18.88% |
| 2018 Q3 | -1.14 Million USD | 13.26% |
| 2018 Q2 | -1.31 Million USD | 43.63% |
| 2018 Q1 | -2.33 Million USD | -6.36% |
| 2018 FY | -6.14 Million USD | -16.33% |
| 2017 FY | -5.28 Million USD | -33.85% |
| 2017 Q4 | -2.19 Million USD | -38.64% |
| 2017 Q3 | -1.58 Million USD | -85.29% |
| 2017 Q2 | -853.73 Thousand USD | -30.82% |
| 2017 Q1 | -652.58 Thousand USD | 52.31% |
| 2016 Q1 | -722.81 Thousand USD | 33.7% |
| 2016 FY | -3.94 Million USD | 38.24% |
| 2016 Q4 | -1.36 Million USD | -58.87% |
| 2016 Q3 | -861.32 Thousand USD | 13.28% |
| 2016 Q2 | -993.18 Thousand USD | -37.4% |
| 2015 FY | -6.38 Million USD | -800.9% |
| 2015 Q3 | -2 Million USD | -31.95% |
| 2015 Q2 | -1.51 Million USD | 0.0% |
| 2015 Q1 | -1.51 Million USD | -738.44% |
| 2015 Q4 | -1.09 Million USD | 45.58% |
| 2014 Q4 | -181.08 Thousand USD | 0.0% |
| 2014 FY | -709.15 Thousand USD | 15.24% |
| 2013 FY | -836.61 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 102.597% |
| Embecta Corp. | 221.5 Million USD | 101.958% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 109.232% |
| Dynavax Technologies Corporation | -37.02 Million USD | 88.289% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 97.213% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 104.946% |
| PainReform Ltd. | -9.58 Million USD | 54.755% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 71.286% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 9.383% |
| SCYNEXIS, Inc. | 72.66 Million USD | 105.967% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -72.403% |
| Cosmos Health Inc. | -21.83 Million USD | 80.137% |
| Journey Medical Corporation | -2.07 Million USD | -109.181% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 9.383% |
| Safety Shot Inc | -12.18 Million USD | 64.41% |
| Alpha Teknova, Inc. | -35.56 Million USD | 87.807% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 97.279% |
| Bright Green Corporation | -8.89 Million USD | 51.23% |
| Procaps Group, S.A. | 38.97 Million USD | 111.126% |
| Theratechnologies Inc. | -10.62 Million USD | 59.195% |
| Harrow Health, Inc. | 580 Thousand USD | 847.641% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 7.758% |
| Biofrontera Inc. | -22.67 Million USD | 80.878% |
| DURECT Corporation | -36.88 Million USD | 88.243% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 17.701% |
| Cronos Group Inc. | -81.37 Million USD | 94.671% |
| OptiNose, Inc. | -22.74 Million USD | 80.938% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 102.074% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 88.925% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 134.328% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 134.621% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 30.181% |
| Radius Health, Inc. | -3.92 Million USD | -10.479% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -22.954% |
| ProPhase Labs, Inc. | -21.61 Million USD | 79.937% |
| Phibro Animal Health Corporation | 53.31 Million USD | 108.133% |
| Procaps Group S.A. | 52.32 Million USD | 108.287% |
| Alvotech | -354.86 Million USD | 98.778% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 49.122% |
| Viatris Inc. | 766.2 Million USD | 100.566% |
| Rockwell Medical, Inc. | -6.67 Million USD | 34.988% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 17.466% |
| SIGA Technologies, Inc. | 83.62 Million USD | 105.186% |
| Tilray Brands, Inc. | -174.74 Million USD | 97.518% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 146.472% |
| Shineco, Inc. | -17.06 Million USD | 74.591% |
| PetIQ, Inc. | 60.01 Million USD | 107.225% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 8.453% |
| Incannex Healthcare Limited | -30.04 Million USD | 85.565% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 101.728% |
| Alimera Sciences, Inc. | -1.47 Million USD | -194.787% |
| Silver Spike Investment Corp. | 7.34 Million USD | 159.077% |
| Assertio Holdings, Inc. | -243.53 Million USD | 98.219% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 26.408% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 68.156% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 72.192% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 78.373% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 96.854% |
| Hempacco Co., Inc. | -8.81 Million USD | 50.792% |
| Talphera, Inc. | -16.88 Million USD | 74.325% |
| Alvotech | -354.86 Million USD | 98.778% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 108.112% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.189% |
| Currenc Group, Inc. | -6.64 Million USD | 34.751% |
| Kamada Ltd. | 10.06 Million USD | 143.087% |
| Indivior PLC | -4 Million USD | -8.408% |
| Evoke Pharma, Inc. | -7.43 Million USD | 41.645% |
| Flora Growth Corp. | -50.35 Million USD | 91.388% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 78.373% |
| Evolus, Inc. | -49.23 Million USD | 91.192% |
| HUTCHMED (China) Limited | 18.37 Million USD | 123.599% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 102.201% |
| Akanda Corp. | -10.05 Million USD | 56.858% |